Fetuses of Obese Mothers Develop Insulin Resistance in Utero by Catalano, Patrick M. et al.
Fetuses of Obese Mothers Develop Insulin
Resistance in Utero
PATRICK M. CATALANO, MD
LARRAINE PRESLEY, MS
JUDI MINIUM
SYLVIE HAUGUEL-DE MOUZON, PHD
OBJECTIVE — Offspring of obese mothers have an increased risk for obesity and diabetes.
The purpose of this study was to determine whether fetuses of obese women have increased
obesity, insulin resistance, and markers of inﬂammation, supporting the concept of fetal
programming.
RESEARCH DESIGN AND METHODS — Fifty-three lean and 68 obese women with
singleton term pregnancies were evaluated at elective cesarean delivery. Maternal and umbilical
cord blood was obtained for measures of insulin resistance and cytokines. Neonatal body com-
position was estimated using anthropometric measurements within 24 h of delivery.
RESULTS — Thefetusesofobesemothershadgreaterpercentbodyfat(13.13.4vs.11.6
2.9%, P  0.02), homeostasis model assessment of insulin resistance (1.51  0.86 vs. 1.06 
0.70, P  0.003), cord leptin (14.5  13.5 vs. 8.2  4.7 ng/ml, P  0.001), and interleukin-6
(3.52.3vs.2.41.4pg/ml,P0.02)thanfetusesofleanwomen.Therewasastrongpositive
correlation between fetal adiposity and insulin resistance (r  0.32, P  0.0008) as well as
maternal pregravid BMI and fetal insulin resistance (r  0.31, P  0.007) even with adjustment
for potential confounders. Cord leptin had a signiﬁcant correlation with fetal insulin resistance
(r0.30,P0.001),buttherewasnosigniﬁcantcorrelationbetweenanyotherumbilicalcord
cytokines and fetal insulin resistance.
CONCLUSIONS — Thesedatasuggestthatmaternalobesitycreatesasigniﬁcantriskforthe
next generations with metabolic compromise already apparent at birth. Therefore, if prevention
of obesity is the goal rather than treatment, the perinatal period may be an important focus of
future research.
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T
hesigniﬁcantincreasesinadultobe-
sity and type 2 diabetes are clearly
public health problems in devel-
oped countries and soon will be, if they
are not already, signiﬁcant medical and
economic issues in developing countries
because of their enormous populations.
Obesity and type 2 diabetes are part of a
larger syndrome of metabolic dysregula-
tion termed the metabolic syndrome (1).
Aggressivetreatmentlaterinthecourseof
type2diabetesmayimproveclinicalmea-
sures such as A1C but unfortunately may
not decrease sequelae such as macrovas-
cular complications (2). Unfortunately,
the prevalence of obesity continues to in-
crease unabated in adolescent populations
with concurrent metabolic abnormalities
(3). The question is then, when should we
begin to treat or, better still, initiate preven-
tive measures?
Based on the developmental origins
of the health and disease hypothesis or
fetal programming (4), the intrauterine
environment represents a time when
changes in maternal metabolism may af-
fect distant metabolic dysfunction in the
offspring mediated through physiological
and/or epigenetic mechanisms. Long-
term follow-up studies have reported an
increase in obesity and type 2 diabetes in
offspring of women who are either obese
and/or diabetic during pregnancy (5).
However, given that 60% of women of
reproductive age are either overweight or
obese (6) and only 5–10% of pregnant
women have a diagnosis of diabetes dur-
ing pregnancy (7), we have chosen to fo-
cus on the greater population risk of
maternal obesity affecting long-term neo-
natal outcomes.
In the last decade, much research
has focused on the relationship among
inﬂammation, obesity, and insulin resis-
tance as putative factors for the develop-
ment of the metabolic syndrome in
adults. However, previous reports have
indicated that at birth, term infants of
overweight and obese women with nor-
mal glucose tolerance have increased fat
mass in comparison with those of lean or
average weight women (8). Because the
infantsofobesewomenhaveanincreased
risk of adolescent obesity and metabolic
dysregulation (9), the objective of these
studies was to determine whether at birth
neonates of obese women, in addition to
increased adiposity, have increased insu-
lin resistance and inﬂammatory markers.
If so, these data would give further sup-
port to the concept that the intrauterine
environment is a critical epoch for inves-
tigation in the prevention of later meta-
bolic dysfunction.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the hospital institutional re-
view board, and written informed
consent was obtained from each subject.
Maternal prepregnancy weight was ob-
tained by history and height measured at
the ﬁrst antenatal visit using a stadiom-
eter. A total of 53 lean (BMI 25 kg/m
2)
and 68 obese (BMI 30 kg/m
2) healthy
women with a singleton-term pregnancy
were recruited at the time of elective ce-
sarean delivery at term (37–40 weeks)
with no clinical evidence of infection. Of
the cesarean sections, 113 were elective
repeat cesarean deliveries. Seven of the
cesareandeliverieswereprimarycesarean
deliveries because of breech presentation
(3), a history of inﬂammatory bowel dis-
ease (1), macrosomia (2), and maternal
request(1).Normalglucosetolerancewas
basedona1-h50-gglucosechallengetest
result 135 mg/dl or, if the result was
positive, a 100-g oral glucose tolerance
test according to the criteria of Carpenter
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obtained on admission for labor and de-
livery,beforeplacementofanintravenous
line for hydration. Umbilical venous
blood was drawn via syringe from the
double-clamped cord immediately after
delivery of the placenta. Plasma was sep-
arated by centrifugation and kept frozen
at 20°C for glucose, insulin, and
cytokineassays.Insulinresistancewases-
timated using homeostasis model assess-
ment (HOMA-IR) (11). Placenta weight
wasrecordedaftertrimmingoftheumbil-
icalcordandfetalmembranesbyresearch
staff. Neonatal body composition mea-
surements were obtained within 24 h of
delivery by one examiner experienced in
the technique. The variables included
weight on a calibrated scale, length using
a measuring board, and abdominal skin-
fold measures. This methodology has
been published previously and correlates
strongly (r
2  0.84) with estimates using
total body electrical conductivity (12).
Plasma assays
Plasma glucose was assessed by the glu-
cose oxidase method (YSI, Yellow
Springs, OH). Plasma insulin was mea-
sured using a radioimmunoassay kit
(LincoResearch,St.Charles,MO).Leptin
and adiponectin were measured using
ELISA kits (Linco Research) with intra-
assay coefﬁcients of variation (CVs) of
3.0–6.2 and 6.2–8.4%. Plasma tumor
necrosis factor- (TNF-) and interleu-
kin-6 (IL-6) were assayed by ELISA
(QuantiGlo; R&D Systems, Minneapolis,
MN) with CVs of 5.3–7.8 and 2.6–3.4%.
Plasma C-reactive protein (CRP) was
measured by ELISA (Alpha Diagnostics
International,SanAntonio,TX)withaCV
of 3.0–4.7%. All plasma samples were
run in duplicate. The insulin resistance
indexes were calculated according to
HOMA-IR: (fasting plasma insulin [mi-
crounits per milliliter]  fasting glucose
[millimoles per liter])/22.5 (11).
Statistical analysis
AllvaluesarepresentedasmeansSDor
in the ﬁgures as means  SEM. Differ-
ences between dependent variables were
examined with one-way or two-way re-
peated-measures ANOVA and adjusted
for potential cofounders using ANCOVA.
Statistically signiﬁcant mean differences
were identiﬁed with a Fisher’s protected
least signiﬁcant difference post hoc test.
The relationship between maternal and
fetalinsulinsensitivitywasestimatedwith
univariate correlation analysis and ad-
justed for potential confounders using
partial correlations. The data were ana-
lyzed using the Statview II statistical
package(AbacusConcepts,Berkeley,CA)
andStatistix8.0(AnalyticalSoftware,Tal-
lahassee, FL). Statistical signiﬁcance was
set at P  0.05.
RESULTS
Anthropometric and metabolic
measures
The anthropometric and metabolic pa-
rameters of the lean and obese mothers
and their offspring are presented in Table
1. Consistent with their increase in BMI,
the obese mothers had a signiﬁcant in-
crease in fasting insulin and glucose com-
pared with lean mothers. There were no
major differences when the maternal
analyses were adjusted for maternal race,
smoking, or medical problems, such as
hypertension. Consistent with what we
reported previously in a different cohort,
the fetuses of obese mothers had no sig-
niﬁcantdifferencesinweightorleanbody
mass at birth, but they had signiﬁcantly
increased fat mass and percent body fat
compared with the fetuses of the lean
mothers(8).Theponderalindex([weight
in grams divided by length in cubic cen-
timeters]  100), a neonatal anthropo-
metric measure of obesity comparable to
theBMI,wasalsoincreasedaswasplacen-
tal weight in the obese cohort. Similar to
their mothers, fetuses of the obese moth-
ershadsigniﬁcantlygreaterfastingumbil-
ical cord insulin and glucose than fetuses
oftheleanmothers.Theresultsweresim-
ilar when the neonatal analyses were ad-
justed for sex, race, smoking, or maternal
medical problems, except that the differ-
ences in umbilical cord glucose became
marginally signiﬁcant (P  0.07).
Cytokine and inﬂammatory factors
The obese mothers had increased plasma
leptin, IL-6, and CRP concentrations but
no difference in circulating TNF- or adi-
ponectin concentrations (Table 2). There
were no major differences when the mater-
nal analyses were adjusted for maternal
race, smoking, or medical problems. Be-
cause of their increased adiposity, the fe-
tuses of obese women had higher umbilical
cord leptin levels than the lean fetuses. Al-
Table 1—Anthropometrics and metabolic parameters of lean and obese mothers and their
offspring at delivery
Lean mothers Obese mothers P
Adjusted
P value
n 53 68
Maternal age (years) 28.0  6.0 27.8  5.8 0.91 0.51
Prepregnancy BMI (kg/m
2) 22.0  1.9 38.4  6.3 0.0001
Late pregnancy BMI (kg/m
2) 28.2  3.2 43.0  6.4 0.0001
Maternal total weight gain (kg) 16.5  7.5 11.9  7.5 0.001 0.008
Maternal net weight gain (kg) 12.8  7.3 7.8  7.2 0.0003 0.001
Maternal insulin (	U/ml) 11.8  5.6 26.0  14.6 0.0001 0.0001
Maternal glucose (mg/dl) 74  77 9  11 0.009 0.006
Gestational age (weeks) 38.8  0.5 38.8  0.6 0.54 0.57
Birth weight (g) 3217  452 3320  460 0.22 0.05
Birth length (cm) 49.1  1.8 48.9  1.9 0.63 0.93
Neonatal lean mass (g) 2828  325 2868  312 0.51 0.17
Neonatal body fat (%) 11.6  2.9 13.1  3.4 0.02 0.001
Neonatal fat mass (g) 384  150 448  175 0.04 0.005
Ponderal index 2.7  0.2 2.8  0.2 0.004 0.001
Placenta weight (g) 614  152 693  184 0.01 0.002
Umbilical cord insulin (	U/ml) 7.0  3.8 9.2  4.7 0.008 0.02
Umbilical cord glucose (mg/dl) 60  13 66  14 0.03 0.07
Smoking status: yes/no 13/40 16/52 0.90
Hypertension: yes/no/pregnancy-
associated 0/53/0 4/60/4 0.04
Race: African American/Asian/
Caucasian/Hispanic 7/1/40/5 29/0/36/3 0.004
Neonatal sex: female/male 26/27 27/41 0.30
Data are means  SD or n. Maternal comparisons were adjusted for race, medical problems, and smoking.
Neonatal and umbilical cord measurements were adjusted for race, medical problems, smoking, and sex.
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in umbilical cord TNF-and a trend for an
increase in CRP, umbilical cord IL-6 was
signiﬁcantly greater in obese than in lean
fetuses. There were again no major differ-
ences when the neonatal analyses were ad-
justed for sex, race, smoking, or maternal
medical problems (Table 2).
Maternal and fetal insulin sensitivity
We estimated insulin resistance in both
mothers and their fetuses after an over-
night fast at the time of elective C-section
using fasting glucose and insulin in the
HOMA-IR model (11). The comparison
oftheHOMA-IRindexesbetweenthelean
and obese fetuses and their mothers is
showninFig.1A.Themothersweremore
insulin resistant than their fetuses (P 
0.0001). As expected, the obese mothers
weremoreinsulinresistantthantheirlean
counterparts (P  0.0001). Similarly, the
fetuses of the obese mothers were also
more insulin resistant (P  0.003) than
the fetuses of lean mothers. As shown in
Fig. 1B, there was a strong positive corre-
lation between maternal and neonatal in-
sulin resistance (r  0.35, P  0.0002).
There was also a positive correlation (r 
0.32, P  0.0008) between fetal insulin
resistanceandfetaladiposity(Fig.2).The
relationships were similar in both the
obese and lean groups. Maternal pre-
gravid BMI was a signiﬁcant correlate
with fetal percent body fat (r  0.31, P 
0.0008), but there was no signiﬁcant cor-
relation between maternal weight gain
(r  0.93, P  0.33) or increase in BMI
(r  0.11, P  0.25) with fetal percent
body fat.
We next examined the relationship
betweenmaternalpregravidBMIandfetal
insulin resistance. The positive relation-
shipbetweenmaternalpregravidBMIand
fetal insulin resistance (r  0.31, P 
0.007) showed that the more obese the
mother is, the more insulin resistant
her fetus is. The correlation remained sig-
niﬁcant (r  0.27, P  0.002) after ad-
justment for the maternal 1-h glucose
screeningvalue,race,ormaternalmedical
problems. The relationship of maternal
pregravid BMI and fetal insulin resistance
also remained signiﬁcant (r  0.24, P 
0.003) after adjustment for fetal fat mass
or percent body fat.
Theadiposityofthefetusesofthelean
and obese women in relation to measures
of HOMA-IR analyzed as quartiles of per-
cent body fat were next evaluated by
ANOVA with assessment of the fetuses in
the lowest and highest quartiles using
Fisher’s protected least signiﬁcant differ-
ence post hoc test. Fetuses of the lean
mothers in the upper quartile (15.5 
1.5% body fat) had signiﬁcantly greater
insulin resistance (P  0.04) than that of
fetuses in the lowest quartile (8.2  1.3%
body fat). Similarly, the fetuses of the
obese mothers in the upper quartile
(17.3  1.4% body fat) had signiﬁcantly
greater insulin resistance (P  0.05) than
the fetuses in the lowest quartile (8.6 
1.4% body fat). Last, there was a signiﬁ-
cant correlation between umbilical cord
leptin and fetal HOMA-IR (r  0.30, P 
0.001) but no signiﬁcant correlation be-
tween umbilical cord adiponectin, TNF-,
and IL-6 and measures of fetal HOMA-IR.
CONCLUSIONS — Excess adipose
tissue combined with low-grade inﬂam-
Figure1—HOMA-IRindexesinfetusesofleanandobesemothers.A:Thefetusesofobesemothers
havehigherHOMA-IRindexes,i.e.,theyaremoreinsulinresistantthanthoseofleanmothers.The
lower HOMA-IR values in offspring compared with mothers are indicative of higher insulin
sensitivity in utero. B: Regression analysis shows a positive correlation between maternal (Mat)
and fetal insulin resistance. E, lean (BMI 25 kg/m
2); F, obese (BMI 30 kg/m
2). Data are
means  SEM. *P  0.003 and **P  0.0001 versus lean.  , lean women and fetuses of lean
women; , obese women and fetuses of obese women.
Table 2—Cytokines and inﬂammatory factors in maternal and umbilical cord plasma at birth
Lean mothers Obese mothers P
Adjusted
P value
n 53 68
Maternal
leptin (ng/ml) 31.9  20.0 72.1  34.7 0.0001 0.0001
adiponectin (	g/ml) 10.7  4.6 9.7  4.0 0.30 0.39
TNF- (pg/ml) 1.4  0.9 1.3  0.5 0.67 0.56
IL-6 (pg/ml) 2.4  1.4 4.6  3.4 0.0001 0.0003
CRP (ng/ml) 8074  6467 12433  7918 0.004 0.01
Umbilical cord
leptin (ng/ml) 8.2  4.7 14.7  13.6 0.001 0.0001
adiponectin (	g/ml) 30.8  10.0 30.6  9.7 0.94 0.71
TNF- (pg/ml) 1.7  0.6 1.7  0.3 0.90 0.67
IL-6 (pg/ml) 2.4  1.4 3.5  2.3 0.02 0.01
CRP (ng/ml) 121  97 202  286 0.25 0.30
DataaremeansSD.Maternalbloodwasobtainedafteranovernightfastatthetimeofadmissionforelective
cesarean section. Umbilical blood was sampled from the clamped cord within 5 min of placental delivery.
Maternalcomparisonswereadjustedforrace,medicalproblems,andsmoking.Neonatalandumbilicalcord
measurements were adjusted for race, medical problems, smoking, and sex.
Figure 2—Relationship of fetal insulin with
fetal adiposity. Regression analyses show a
positive correlation between fetal insulin resis-
tance estimated by HOMA-IR at birth and per-
cent neonatal body fat of the fetus.
Fetuses of obese mothers have insulin resistance
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central feature of the metabolic dysregu-
lation in adult obesity. Therefore, we
asked the question of whether excess ad-
ipose tissue during fetal development
leads to the same pathophysiologic pro-
cesses as in adults, resulting in insulin re-
sistance before birth? To the best of our
knowledge, our ﬁndings are the ﬁrst to
report that fetuses of obese mothers be-
come insulin resistant in utero as esti-
mated by umbilical cord glucose and
insulin concentrations.
In neonates, the measures of insulin
resistance estimated by clamp studies are
low and reﬂect primarily peripheral
rather than hepatic insulin resistance
(13), as the enzyme required for glucone-
ogenesis, phosphoenolpyruvate car-
boxykinase, does not increase until after
birth. Hence, the estimates of insulin re-
sistance in our study are also likely to re-
ﬂect primarily peripheral and not hepatic
insulin resistance. We recognize that
there is limited information on the meta-
bolic status of the neonate relative to in-
sulin resistance. Dyer (14), using a
minimal model technique, described in-
creased insulin resistance in large-for-
gestational-age term neonates compared
with that in poorly grown neonates be-
tween 24–48 h of birth. Our study mea-
suring insulin resistance in fetuses of
fasted mothers (thus, in steady-state gly-
cemic/lipemic conditions) suggests that
HOMA-IR is a reasonable estimate of in-
sulin resistance at birth.
During in utero development, the fetus
reliesprimarilyonglucoseasanenergysub-
strate. There is a steady supply of glucose
even during maternal fasting because of the
30% increase in maternal hepatic glucose
production in late gestation (15). Maternal
insulinresistanceduringgestationresultsin
increased lipolysis with increased availabil-
ity of free fatty acids to be used as adipo-
genic substrates in the fetus. Therefore,
understanding the mechanisms through
whichafetusgrowinginanutrient-richen-
vironment becomes insulin resistant is a
major challenge. Fetal hyperinsulinemia
haslongbeenacceptedasananabolicfactor
during in utero development, resulting in
fetal overgrowth, particularly in women
with diabetes, i.e., the Pedersen hypothesis
(16). The recently published Hyperglyce-
mia and Adverse Pregnancy Outcomes
(HAPO)studyreportedastrongassociation
between umbilical cord C-peptide and fetal
adiposity in women with glucose concen-
trations less than those for overt diabetes
(17).Wefoundsimilarincreasesincordin-
sulin in our study cohort of fetuses of obese
pregnant women (Table 1). The anabolic
effect of insulin is likely to contribute to an
increase in fat mass in utero.
Thereisadearthofanimaldatainthis
area because of species differences in fetal
adiposity, i.e., the human fetus has a
greater percent fat mass at birth than fe-
tuses of most other mammalian species
(18).Susaetal.(19)showedthatimplant-
ing an Alzet pump delivering insulin into a
fetal rhesus monkey resulted in increased
fetal growth including adipose tissue with-
out a change in maternal diet. Our ﬁndings
againhighlighttheassociationbetweenfetal
hyperinsulinemia and increased fat deposi-
tioninutero.Limitedglucoseexcursionsre-
sulting in mild hyperglycemia in obese
women with otherwise normal glucose tol-
erance may be sufﬁcient to modify fetal en-
ergy homeostasis.
Is the fetus developing insulin resis-
tancebecauseofexcessfatmass?Wecannot
answer this question directly. We have
shown that increased fetal adiposity and fe-
tal insulin resistance are closely associated
(Fig. 2). However, maternal obesity had a
strongpositivecorrelationwithfetalinsulin
resistance even when adjusted for various
maternal confounders including fetal adi-
posity. These data suggest the possibility of
genetic or potential epigenetic factors relat-
ing to fetal insulin resistance.
Whatismostapparentisthatfetalcir-
culating cytokines, save for leptin synthe-
sized by fetal adipose tissue, are not
correlated with insulin resistance. The in-
crease in umbilical cord plasma IL-6 in
the obese fetus may only reﬂect an in-
crease in total fat mass. Whether there is
evidence for inﬂammation of white adi-
pose tissue in the obese fetus similar to
that found in obese adult individuals is
not known. Macrophage inﬁltration of
white adipose tissue, however, is present
in the white adipose tissue of insulin-
resistant children (20).
Our results are in contrast with evi-
dence of inﬂammation in infants of
women with type 1 diabetes (21). Nelson
et al. (21) reported that umbilical cord
concentrationsofCRP,IL-6,andintercel-
lular adhesion molecule-1 were increased
and adiponectin concentrations were de-
creased in infants of women with type 1
diabetes compared with those of control
subjects. Although in their study insulin
resistance was not estimated, the inﬂam-
matory markers in umbilical cord blood
were related to measures of umbilical lep-
tin and fetal adiposity. Thus, the relation-
ships of increased adiposity, insulin
resistance, and circulating cytokines in
the fetus have yet to be deﬁned.
Based on the developmental origins
of the health and disease hypothesis, fetal
development in utero may present a par-
ticularly vulnerable time period for the
maternal environment to affect long-term
growth and energy metabolism. We de-
scribe here major changes in the meta-
bolichomeostasisofobesewomen,which
alters the environment in which the feto-
placental unit develops. These data are
consistent with previous reports charac-
terizing pregnancy in obese women as an
inﬂammatory condition. Stewart et al.
(22) also described an increase in IL-6 and
CRP in obese compared with lean women
in late gestation. Therefore, maternal obe-
sity in addition to the signiﬁcant 60% in-
crease in insulin resistance of normal
pregnancy (15) results in an increased in-
ﬂammatory state. Most cytokines do not
crosstheplacenta;thus,ourresultssupport
the concept that maternal inﬂammation
linked to obesity does not directly translate
into fetal inﬂammation (23).
We know that maternal obesity is a
risk factor for offspring developing the
metabolicsyndromelaterinlife;theques-
tion is when does the pathophysiologic
process begin? Mingrone et al. (24), in a
follow-upstudyofyoungadults,reported
that the offspring of obese women had
signiﬁcantly greater insulin resistance
than offspring of a control group whose
mothers had a pregnancy BMI 25 kg/
m
2. Similarly, Boney et al. (9) reported
that neonates of obese mothers with nor-
mal glucose tolerance had an increased
risk of developing the metabolic syn-
drome at age 11 of almost twofold (1.81,
95% CI 1.03–3.19) compared with neo-
natesofanonobesegroup.Last,Whitaker
(25) reported that children born to obese
women had a 2.5-fold increase of obesity
at 2–4 years of age (BMI 95% based on
Centers for Disease Control and Preven-
tioncriteria)comparedwiththosebornto
leanoraverageweightwomen.Ourstudy
extendsthesereportstotheperiodofpre-
natal development and emphasizes that
fetuses of obese mothers already repre-
sent a group at high risk for later disease.
Insummary,onthebasisofthesedata
weconcludethatmaternalobesitycreates
a signiﬁcant risk for the next generations
with metabolic compromise already ap-
parent before birth. If prevention is the
goal to stem the epidemic of obesity and
related problems, then the perinatal pe-
riodofdevelopmentmaybeanimportant
focus of additional research. Until we at-
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lying genetic predispositions, physiology,
and mechanisms relating to maternal and
fetoplacental interactions, strategies to
counteract the epidemic of obesity must,
by necessity, be considered treatment
rather than prevention.
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